NCT04165239 - The KHENERGYZE Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions

Mitochondrial DiseasesMitochondrial MyopathiesMitochondrial EncephalomyopathiesMELAS SyndromeMIDD

Interventions

DRUG

KH176

Oral administration of 50 mg KH176 twice daily

DRUG

KH176

Oral administration of 100 mg KH176 twice daily

DRUG

Placebo

Oral administration of matching placebo twice daily

Trial Locations (4)

Friedrich-Baur Institut, München

Rigshospitalet, University of Copenhagen, Copenhagen

Radboud University Medical Center, Nijmegen

Institute for Ageing and Health Newcastle University, Newcastle upon Tyne